{"disease":{"id":"geographic-atrophy-secondary-to-age-related-macular-degeneration","name":"Geographic atrophy secondary to age-related macular degeneration","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"avacincaptad","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avacincaptad","company_name":"Aviceda Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04770545","title":"An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":792,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07441642","title":"A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06662162","title":"Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"i-Lumen Scientific AUS PTY LTD","has_results":false},{"nct_id":"NCT07392255","title":"An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT07144137","title":"A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT06765980","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Kriya Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07214740","title":"Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}